---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Specific populations questions"
description: "Specific populations questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Do older adults respond differently to Verzenio? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Specific populations questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Specific populations questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications: Specific populations](https://www.evicenter.com/medical-information/verzenio/specific-populations).

## Specific populations

<a id="verzenio-older-adults"></a>

### Do older adults respond differently to Verzenio?

> “Of the 2791 VERZENIO-treated patients in monarchE, 15% were 65 years of age or older and 2.7% were 75 years of age or older.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Of%20the%202791%20VERZENIO%2Dtreated%20patients,years%20of%20age%20or%20older.)

> “No overall differences in safety or effectiveness of VERZENIO as monotherapy or in combination with fulvestrant, tamoxifen, or an aromatase inhibitor have been observed between these patients and younger patients.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=No%20overall%20differences%20in%20safety,these%20patients%20and%20younger%20patients.)

Note: In the Prescribing Information the statement follows the counts for monarchE and for MONARCH 1, MONARCH 2, and MONARCH 3. Section 5.3 of the Prescribing Information describes MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3 as trials in advanced or metastatic breast cancer.

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines)
